Fig. 5From: A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeuticPharmacokinetic profiles of VGRmIL2-IC, wtIL-2, and mIL-2 in mice. Monitoring of wtIL-2 and mIL-2 was performed for up to 48Â h. Cytokines were not detectable in the plasma after 24Â hBack to article page